PERK Inhibition Mitigates Restenosis and Thrombosis: A Potential Low-Thrombogenic Antirestenotic Paradigm.

Publications // Shaoqin Gong // Mar 01 2020

PubMed ID: 32215348

Author(s): Wang B, Zhang M, Urabe G, Huang Y, Chen G, Wheeler D, Dornbos DJ 3rd, Huttinger A, Nimjee SM, Gong S, Guo LW, Kent KC. PERK inhibition mitigates restenosis and thrombosis: A potential low-thrombogenic antirestenotic paradigm. JACC Basic Transl Sci. 2020 Feb 19;5(3):245-263. doi: 10.1016/j.jacbts.2019.12.005. eCollection 2020 Mar. PMID 32215348

Journal: Jacc. Basic To Translational Science, Volume 5, Issue 3, Mar 2020

Developing endothelial-protective, nonthrombogenic antirestenotic treatments has been a challenge. A major hurdle to this has been the identification of a common molecular target in both smooth muscle cells and endothelial cells, inhibition of which blocks dysfunction of both cell types. The authors’ findings suggest that the PERK kinase could be such a target. Importantly, PERK inhibition mitigated both restenosis and thrombosis in preclinical models, implicating a low-thrombogenic antirestenotic paradigm.

© 2020 The Authors.